LifeScience Biologics

Chemotherapy may be completed within 8 days with two doses of Polytaxel, an innovative anticancer drug from South Korea's biotech firm

Polytaxel, a novel pain-free anticancer drug, may not require break periods A new standard of care, more convenient than docetaxel, is suggest...

 November 28, 2022 | News

Fujifilm Invests $188 Million in New Cell Culture Media Manufacturing Facility

Fujifilm’s fifth media manufacturing site to be operated by FUJIFILM Irvine Scientific Triples the company’s current capacity for liquid cel...

 November 23, 2022 | News

Merck to Acquire Imago BioSciences, Inc.

 Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO) today announce...

 November 22, 2022 | News

Indonesia to Advance Genomic Sequencing and Bioinformatics

Signing Ceremony Memorandum of Understanding between Asa Ren (Indonesia) and G42 Healthcare (United Arab Emirates) on 14 November 2022. From left to righ...

 November 18, 2022 | News

New CRISPR/Cas9 Agreement for ERS Genomics and ATLATL

ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to the foundational CRISPR/Cas9 intellectual ...

 November 18, 2022 | News

Stealth BioTherapeutics Corp Announces Completion of Merger

Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the discov...

 November 17, 2022 | News

Monash University Implements Antibody Discovery Application by Utilizing the Berkeley Lights Beacon® Platform

The technology is housed in the Monash Antibody Technology Facility (MATF) where researchers not only from Monash University but elsewhere in Victoria...

 November 10, 2022 | News

XJTLU and University of Liverpool to inaugurate Joint Centre for Pharmacology and Therapeutics

Xi'an Jiaotong-Liverpool University (XJTLU) researchers conduct world-class biopharmaceutical research at the University's Suzhou Industrial Park (SIP) c...

 November 09, 2022 | News

Cyagen and Neurophth Enter Global Strategic Collaboration to Develop AI-Designed AAV Gene Therapy Vectors for Ophthalmic Disorders

Under the terms of the agreement, Cyagen will apply its proprietary artificial intelligence (AI)-powered high-throughput platform to discover novel AAV vec...

 November 08, 2022 | News

Brexogen's Exosome Therapy for Atopic Dermatitis, 'BRE-AD01' Accepted for Phase 1 Clinical Trials by US FDA

The US FDA granted the initiation of the phase 1 clinical trial of 'BRE-AD01', an exosome- based therapy for atopic dermatitis. 'BRE-AD01' is being develop...

 November 07, 2022 | News

I Peace partners with the California Institute for Regenerative Medicine [CIRM]

 I Peace has been providing GMP Induced Pluripotent Stem Cells (iPSC) for a variety of cell therapy developers and pharmaceutical companies in the pas...

 November 02, 2022 | News

Thermo Fisher Scientific to Acquire The Binding Site Group

Complements Existing Specialty Diagnostics Offering with Established Technologies Delivering Strong Clinical Value for Patients in a Rapidly Growing...

 November 01, 2022 | News

Register Now | Learn how Optimer ligands can be developed in a biomarker-free way to open up new targets for challenging diseases

    Speakers Dr David Bunka Chief Technical Officer Synopsis Dev...

 October 28, 2022 | News

Polyplus and ENcell sign MOU for gene therapy discovery and optimization projects in Korea

“ENCell is working to accelerate viral vector CMO business via a collaboration with Polyplus.”, said Dr. Jong Wook Chang, CEO of ENCell. &ldquo...

 October 28, 2022 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close